Announcement • 10h
Chengdu Easton Biopharmaceuticals Co., Ltd. to Report First Half, 2026 Results on Aug 21, 2026 Chengdu Easton Biopharmaceuticals Co., Ltd. announced that they will report first half, 2026 results on Aug 21, 2026 Announcement • Jun 05
Chengdu Easton Biopharmaceuticals Co., Ltd. (SHSE:688513) announces an Equity Buyback for CNY 100 million worth of its shares. Chengdu Easton Biopharmaceuticals Co., Ltd. (SHSE:688513) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The repurchase price does not exceed CNY 80 per share. The program will be funded from the company's own funds. The purpose of the program is to maintain the company’s value and shareholder rights. The shares will be sold 12 months after the completion of the repurchase and within 3 years after the completion of the repurchase. Shares not sold will be cancelled. The repurchase program is valid for 3 months from company's Directorate's Approval Date. Declared Dividend • Jun 01
Dividend increased to CN¥0.49 Dividend of CN¥0.49 is 14% higher than last year. Ex-date: 2nd June 2026 Payment date: 2nd June 2026 Dividend yield will be 0.9%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is well covered by both earnings (31% earnings payout ratio) and cash flows (39% cash payout ratio). The dividend has increased by an average of 19% per year over the past 5 years. However, payments have been volatile during that time. EPS is expected to grow by 16% over the next year, which should provide support to the dividend and adequate earnings cover. Valuation Update With 7 Day Price Move • May 26
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥47.62, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total returns to shareholders of 26% over the past three years. New Risk • May 11
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 24% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.3% average weekly change). Large one-off items impacting financial results. Reported Earnings • Apr 22
First quarter 2026 earnings released: EPS: CN¥0.29 (vs CN¥0.34 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.29 (down from CN¥0.34 in 1Q 2025). Revenue: CN¥326.3m (up 6.7% from 1Q 2025). Net income: CN¥50.8m (down 16% from 1Q 2025). Profit margin: 16% (down from 20% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 22
Chengdu Easton Biopharmaceuticals Co., Ltd., Annual General Meeting, May 13, 2026 Chengdu Easton Biopharmaceuticals Co., Ltd., Annual General Meeting, May 13, 2026, at 14:00 China Standard Time. Location: No. 8, Ankang Road, Shuangliu District, Chengdu, Sichuan China New Risk • Apr 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.6% average weekly change). Announcement • Mar 30
Chengdu Easton Biopharmaceuticals Co., Ltd. to Report Q1, 2026 Results on Apr 22, 2026 Chengdu Easton Biopharmaceuticals Co., Ltd. announced that they will report Q1, 2026 results on Apr 22, 2026 Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥66.38, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total returns to shareholders of 89% over the past three years. Reported Earnings • Mar 02
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: EPS: CN¥1.63 (up from CN¥1.36 in FY 2024). Revenue: CN¥1.33b (down 1.4% from FY 2024). Net income: CN¥283.2m (up 19% from FY 2024). Profit margin: 21% (up from 18% in FY 2024). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 4.4%. Earnings per share (EPS) exceeded analyst estimates by 7.9%. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 15% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Feb 03
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to CN¥68.90, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total returns to shareholders of 83% over the past three years. Announcement • Dec 26
Chengdu Easton Biopharmaceuticals Co., Ltd. to Report Fiscal Year 2025 Results on Apr 22, 2026 Chengdu Easton Biopharmaceuticals Co., Ltd. announced that they will report fiscal year 2025 results on Apr 22, 2026 Reported Earnings • Oct 28
Third quarter 2025 earnings released: EPS: CN¥0.48 (vs CN¥0.41 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.48 (up from CN¥0.41 in 3Q 2024). Revenue: CN¥364.7m (down 1.5% from 3Q 2024). Net income: CN¥83.6m (up 19% from 3Q 2024). Profit margin: 23% (up from 19% in 3Q 2024). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Announcement • Sep 30
Chengdu Easton Biopharmaceuticals Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025 Chengdu Easton Biopharmaceuticals Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025 Buy Or Sell Opportunity • Sep 26
Now 23% undervalued Over the last 90 days, the stock has risen 35% to CN¥54.85. The fair value is estimated to be CN¥70.84, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.7% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 44% in 2 years. Earnings are forecast to grow by 49% in the next 2 years. Buy Or Sell Opportunity • Sep 09
Now 21% undervalued Over the last 90 days, the stock has risen 28% to CN¥56.00. The fair value is estimated to be CN¥70.84, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.7% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 44% in 2 years. Earnings are forecast to grow by 49% in the next 2 years. Reported Earnings • Aug 20
Second quarter 2025 earnings released: EPS: CN¥0.43 (vs CN¥0.40 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.43 (up from CN¥0.40 in 2Q 2024). Revenue: CN¥348.8m (down 1.6% from 2Q 2024). Net income: CN¥76.0m (up 6.3% from 2Q 2024). Profit margin: 22% (up from 20% in 2Q 2024). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings. New Risk • Jul 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 8.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.6% average weekly change). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Jul 22
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥49.33, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 22x in the Pharmaceuticals industry in China. Total returns to shareholders of 24% over the past three years. Announcement • Jun 30
Chengdu Easton Biopharmaceuticals Co., Ltd. to Report First Half, 2025 Results on Aug 19, 2025 Chengdu Easton Biopharmaceuticals Co., Ltd. announced that they will report first half, 2025 results on Aug 19, 2025 New Risk • Jun 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.3% average weekly change). Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • May 29
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥41.26, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total returns to shareholders of 18% over the past three years. Major Estimate Revision • May 22
Consensus revenue estimates fall by 14% The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥1.76b to CN¥1.52b. EPS estimate fell from CN¥1.92 to CN¥1.52 per share. Net income forecast to grow 34% next year vs 25% growth forecast for Pharmaceuticals industry in China. Consensus price target down from CN¥47.00 to CN¥43.00. Share price rose 7.5% to CN¥35.70 over the past week. Reported Earnings • Apr 25
First quarter 2025 earnings released: EPS: CN¥0.34 (vs CN¥0.43 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.34 (down from CN¥0.43 in 1Q 2024). Revenue: CN¥305.6m (down 3.0% from 1Q 2024). Net income: CN¥60.6m (down 19% from 1Q 2024). Profit margin: 20% (down from 24% in 1Q 2024). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Announcement • Apr 25
Chengdu Easton Biopharmaceuticals Co., Ltd., Annual General Meeting, May 16, 2025 Chengdu Easton Biopharmaceuticals Co., Ltd., Annual General Meeting, May 16, 2025, at 14:00 China Standard Time. Location: No. 8, Ankang Road, Shuangliu District, Chengdu, Sichuan China Valuation Update With 7 Day Price Move • Apr 02
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥35.30, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total returns to shareholders of 2.5% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥22.41 per share. Announcement • Mar 28
Chengdu Easton Biopharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025 Chengdu Easton Biopharmaceuticals Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025 Reported Earnings • Mar 02
Full year 2024 earnings released: EPS: CN¥1.36 (vs CN¥1.29 in FY 2023) Full year 2024 results: EPS: CN¥1.36 (up from CN¥1.29 in FY 2023). Revenue: CN¥1.35b (up 21% from FY 2023). Net income: CN¥236.6m (up 4.4% from FY 2023). Profit margin: 18% (down from 20% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Announcement • Dec 27
Chengdu Easton Biopharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on Apr 25, 2025 Chengdu Easton Biopharmaceuticals Co., Ltd. announced that they will report fiscal year 2024 results on Apr 25, 2025 Reported Earnings • Oct 25
Third quarter 2024 earnings released: EPS: CN¥0.41 (vs CN¥0.35 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.41 (up from CN¥0.35 in 3Q 2023). Revenue: CN¥370.4m (up 26% from 3Q 2023). Net income: CN¥70.5m (up 13% from 3Q 2023). Profit margin: 19% (down from 21% in 3Q 2023). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Announcement • Sep 30
Chengdu Easton Biopharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024 Chengdu Easton Biopharmaceuticals Co., Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to CN¥40.38, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total returns to shareholders of 40% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥21.59 per share. Valuation Update With 7 Day Price Move • Aug 06
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥33.41, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total returns to shareholders of 6.2% over the past three years. Announcement • Jun 29
Chengdu Easton Biopharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 20, 2024 Chengdu Easton Biopharmaceuticals Co., Ltd. announced that they will report first half, 2024 results on Aug 20, 2024 Announcement • Apr 30
Chengdu Easton Biopharmaceuticals Co., Ltd., Annual General Meeting, May 20, 2024 Chengdu Easton Biopharmaceuticals Co., Ltd., Annual General Meeting, May 20, 2024, at 14:00 China Standard Time. Location: No. 8, Ankang Road, Shuangliu District, Chengdu, Sichuan China Reported Earnings • Apr 24
First quarter 2024 earnings released: EPS: CN¥0.63 (vs CN¥0.51 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.63 (up from CN¥0.51 in 1Q 2023). Revenue: CN¥315.0m (up 13% from 1Q 2023). Net income: CN¥75.0m (up 23% from 1Q 2023). Profit margin: 24% (up from 22% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 10% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Mar 29
Chengdu Easton Biopharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024 Chengdu Easton Biopharmaceuticals Co., Ltd. announced that they will report Q1, 2024 results on Apr 23, 2024 Reported Earnings • Feb 24
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥1.88 (down from CN¥2.05 in FY 2022). Revenue: CN¥1.12b (down 4.6% from FY 2022). Net income: CN¥226.3m (down 8.2% from FY 2022). Profit margin: 20% (in line with FY 2022). Revenue missed analyst estimates by 6.7%. Earnings per share (EPS) also missed analyst estimates by 8.1%. Revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 4% per year and the company’s share price has also increased by 4% per year. Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: CN¥0.51 (vs CN¥0.47 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.51 (up from CN¥0.47 in 3Q 2022). Revenue: CN¥294.4m (down 1.1% from 3Q 2022). Net income: CN¥62.2m (up 11% from 3Q 2022). Profit margin: 21% (up from 19% in 3Q 2022). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 19
Second quarter 2023 earnings released: EPS: CN¥0.59 (vs CN¥0.67 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.59 (down from CN¥0.67 in 2Q 2022). Revenue: CN¥277.5m (down 9.4% from 2Q 2022). Net income: CN¥70.5m (down 13% from 2Q 2022). Profit margin: 25% (down from 26% in 2Q 2022). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Announcement • Aug 17
Chengdu Easton Biopharmaceuticals Co., Ltd. (SHSE:688513) announces an Equity Buyback for CNY 200 million worth of its shares. Chengdu Easton Biopharmaceuticals Co., Ltd. (SHSE:688513) announces a share repurchase program. Under the program, the company will repurchase up to CNY 200 million worth of its shares. The repurchase price does not exceed CNY 73 per share. Repurchased shares will be used for employee stock ownership plans or equity incentives. The repurchase program is valid for 12 months. Announcement • Jun 28
Chengdu Easton Biopharmaceuticals Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023 Chengdu Easton Biopharmaceuticals Co., Ltd. announced that they will report first half, 2023 results on Aug 18, 2023 Reported Earnings • Apr 13
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: EPS: CN¥2.06 (up from CN¥1.94 in FY 2021). Revenue: CN¥1.17b (up 14% from FY 2021). Net income: CN¥247.2m (up 6.4% from FY 2021). Profit margin: 21% (down from 23% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.0%. Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Fang Fang was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 21
Third quarter 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.57 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.51 (down from CN¥0.57 in 3Q 2021). Revenue: CN¥322.2m (up 17% from 3Q 2021). Net income: CN¥60.9m (down 12% from 3Q 2021). Profit margin: 19% (down from 25% in 3Q 2021). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Valuation Update With 7 Day Price Move • Oct 17
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥58.97, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 20x in the Pharmaceuticals industry in China. Total returns to shareholders of 33% over the past year. Reported Earnings • Jul 29
Second quarter 2022 earnings released: EPS: CN¥0.67 (vs CN¥0.62 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.67 (up from CN¥0.62 in 2Q 2021). Revenue: CN¥306.5m (up 11% from 2Q 2021). Net income: CN¥80.8m (up 9.2% from 2Q 2021). Profit margin: 26% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 19%, compared to a 23% growth forecast for the industry in China. Reported Earnings • Apr 27
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2022 results: EPS: CN¥0.45 (up from CN¥0.36 in 1Q 2021). Revenue: CN¥269.0m (up 22% from 1Q 2021). Net income: CN¥53.8m (up 24% from 1Q 2021). Profit margin: 20% (in line with 1Q 2021). Revenue missed analyst estimates by 6.2%. Earnings per share (EPS) exceeded analyst estimates by 4.3%. Over the next year, revenue is forecast to grow 16%, compared to a 26% growth forecast for the industry in China. Reported Earnings • Mar 29
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2021 results: EPS: CN¥1.93 (up from CN¥1.78 in FY 2020). Revenue: CN¥1.02b (up 11% from FY 2020). Net income: CN¥232.3m (up 30% from FY 2020). Profit margin: 23% (up from 19% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 6.2%. Earnings per share (EPS) exceeded analyst estimates by 4.3%. Over the next year, revenue is forecast to grow 30%, compared to a 25% growth forecast for the pharmaceuticals industry in China. Reported Earnings • Feb 28
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: CN¥1.93 (up from CN¥1.78 in FY 2020). Revenue: CN¥1.02b (up 11% from FY 2020). Net income: CN¥232.3m (up 30% from FY 2020). Profit margin: 23% (up from 19% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 6.2%. Earnings per share (EPS) also missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 30%, compared to a 26% growth forecast for the pharmaceuticals industry in China. Reported Earnings • Oct 23
Third quarter 2021 earnings released: EPS CN¥0.57 (vs CN¥0.39 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥274.7m (up 16% from 3Q 2020). Net income: CN¥68.7m (up 77% from 3Q 2020). Profit margin: 25% (up from 16% in 3Q 2020). Reported Earnings • Jul 30
Second quarter 2021 earnings released: EPS CN¥0.62 (vs CN¥0.62 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥277.5m (up 7.3% from 2Q 2020). Net income: CN¥74.1m (up 34% from 2Q 2020). Profit margin: 27% (up from 21% in 2Q 2020). Reported Earnings • Apr 17
First quarter 2021 earnings released: EPS CN¥0.36 (vs CN¥0.48 in 1Q 2020) The company reported a solid first quarter result with improved revenues, although earnings and profit margins were flat. First quarter 2021 results: Revenue: CN¥221.2m (up 1.7% from 1Q 2020). Net income: CN¥43.3m (flat on 1Q 2020). Profit margin: 20% (in line with 1Q 2020). Reported Earnings • Mar 30
Full year 2020 earnings released: EPS CN¥1.78 (vs CN¥1.21 in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: CN¥921.9m (down 2.7% from FY 2019). Net income: CN¥178.2m (up 64% from FY 2019). Profit margin: 19% (up from 12% in FY 2019). The increase in margin was driven by lower expenses. Is New 90 Day High Low • Mar 12
New 90-day low: CN¥44.35 The company is down 13% from its price of CN¥50.99 on 11 December 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period. Announcement • Mar 09
Chengdu Easton Biopharmaceuticals Co., Ltd. to Report Fiscal Year 2020 Results on Mar 30, 2021 Chengdu Easton Biopharmaceuticals Co., Ltd. announced that they will report fiscal year 2020 results on Mar 30, 2021 Reported Earnings • Mar 04
Full year 2020 earnings released: EPS CN¥1.78 (vs CN¥1.21 in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: CN¥921.9m (down 2.7% from FY 2019). Net income: CN¥178.2m (up 64% from FY 2019). Profit margin: 19% (up from 12% in FY 2019). The increase in margin was driven by lower expenses. Is New 90 Day High Low • Dec 28
New 90-day low: CN¥46.55 The company is down 10.0% from its price of CN¥51.62 on 29 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. Is New 90 Day High Low • Dec 11
New 90-day low: CN¥50.99 The company is down 1.0% from its price of CN¥51.27 on 11 September 2020. The Chinese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 6.0% over the same period. 